Skip to main content

Table 2 Details of adverse effects of therapy in both groups.

From: Comparative study of sequential intravesical chemotherapy using gemcitabine and mitomycin C with mitomycin C alone for non-muscle invasive bladder carcinoma- a randomized trial

Parameters Group A Group B P value
  Gemcitabine + MMC Mitomycin C(MMC)  
Dysuria 11.7% (12) 7.2% (7) NS+
Suprapubic pain 11.7% (12) 9.3% (9) NS+
Hematuria 3.9% (4) 3.1% (3) NS+
Chemical Cystitis 7.8% (8) 6.25% (6) NS+
Local reaction 6.8% (7) 4.16% (4) NS+
Skin reaction 5.8% (6) 4.16% (4) NS+
  1. Group A: Gemcitabine & Mitomycin (MMC+Gentamycin)
  2. Group B: Mitomycin C(MMS)
  3. *Statistical significance was analyzed by student t-test
  4. +Statistical significance was analyzed by the chi-square test.